Prime Medicine Analyst Ratings
Prime Medicine Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/06/2023 | 66.67% | JonesTrading | → $20 | Initiates Coverage On | → Buy |
| 08/14/2023 | 58.33% | Morgan Stanley | $21 → $19 | Maintains | Equal-Weight |
| 07/31/2023 | 100% | Guggenheim | → $24 | Initiates Coverage On | → Buy |
| 04/18/2023 | 50% | Stifel | → $18 | Initiates Coverage On | → Buy |
| 01/24/2023 | 75% | Morgan Stanley | $23 → $21 | Maintains | Equal-Weight |
| 11/14/2022 | 125% | JP Morgan | → $27 | Initiates Coverage On | → Overweight |
| 11/14/2022 | 108.33% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/14/2022 | 91.67% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 11/14/2022 | 83.33% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/06/2023 | 66.67% | Jones Trading | →$20 | 開始承保 | →購買 |
| 2023年08月14日 | 58.33% | 摩根士丹利 | $21→$19 | 維護 | 等重 |
| 07/31/2023 | 100% | 古根海姆 | →$24 | 開始承保 | →購買 |
| 04/18/2023 | 50% | Stifel | →$18 | 開始承保 | →購買 |
| 01/24/2023 | 75% | 摩根士丹利 | $23→$21 | 維護 | 等重 |
| 2022年11月14日 | 百分之一百二十五 | 摩根大通 | →$27 | 開始承保 | →超重 |
| 2022年11月14日 | 108.33% | 傑富瑞 | →$25 | 開始承保 | →購買 |
| 2022年11月14日 | 91.67% | 摩根士丹利 | →$23 | 開始承保 | →等重 |
| 2022年11月14日 | 83.33% | 高盛 | →$22 | 開始承保 | →中性 |
What is the target price for Prime Medicine (PRME)?
Prime Medicine(PRME)的目標價格是多少？
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JonesTrading on September 6, 2023. The analyst firm set a price target for $20.00 expecting PRME to rise to within 12 months (a possible 66.67% upside). 9 analyst firms have reported ratings in the last year.
瓊恩斯交易公司於2023年9月6日報道了Prime Medicine(納斯達克代碼：PRME)的最新目標價。這家分析公司將目標價定為20.00美元，預計PRME將在12個月內上漲(可能上漲66.67%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Prime Medicine (PRME)?
最新分析師對Prime Medicine(PRME)的評級是多少？
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JonesTrading, and Prime Medicine initiated their buy rating.
優質醫藥(納斯達克代碼：PRME)的最新分析師評級是由瓊恩斯交易公司提供的，優質醫藥啟動了他們的買入評級。
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Prime Medicine(PRME)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on September 6, 2023 so you should expect the next rating to be made available sometime around September 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Prime Medicine的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Prime Medicine的上一次評級是在2023年9月6日提交的，所以你應該預計下一次評級將在2024年9月6日左右提供。
Is the Analyst Rating Prime Medicine (PRME) correct?
分析師對Prime Medicine(PRME)的評級正確嗎？
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $20.00. The current price Prime Medicine (PRME) is trading at is $12.00, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Prime Medicine(PRME)評級是以0.00美元至20.00美元的目標價啟動的。Prime Medicine(PRME)目前的交易價格為12.00美元，在分析師的預測範圍內。